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Abstract 
 
Increased serum bile salt levels have been associated to a single nucleotide polymorphism in 
the bile salt export pump (BSEP; ABCB11) in several acquired cholestatic liver diseases but there is 
little evidence in alcoholic liver disease (ALD). Furthermore, a cross-talk between vitamin D and bile 
acid synthesis has recently been discovered. Whether this cross-talk has an influence on the course of 
ALD is unclear to date. Our aim was to analyze the role of genetic polymorphisms in BSEP and the 
vitamin D receptor gene (VDR; NR1I1) on the emergence of cirrhosis in patients with ALD. 
Therefore, 511 alcoholic patients (131 with cirrhosis, 380 without cirrhosis) underwent ABCB11 
genotyping (rs2287622). Of these, 321 (131 with cirrhosis, 190 without cirrhosis) were also tested for 
NR1I1 polymorphisms (bat-haplotype: BsmI rs1544410, ApaI rs7975232 and TaqI rs731236). 
Frequencies of ABCB11 and NR1I1 genotypes and haplotypes were compared between alcoholic 
patients with and without cirrhosis and correlated to serum bile salt, bilirubin and aspartate 
aminotransferase levels in those with cirrhosis. Frequencies of ABCB11 and NR1I1 genotypes and 
haplotypes did not differ between the two subgroups and no significant association between 
genotypes/haplotypes and liver function tests could be determined for neither polymorphism. We 
conclude that ABCB11 and NR1I1 polymorphisms are obviously not associated with development of 
cirrhosis in patients with ALD. 
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Introduction 
 
Alcohol has been identified as the third leading global risk factor for disease and disability [1] 
and represents a major cause of liver cirrhosis [2]. The fact that only up to 20% of alcoholics develop 
cirrhosis [3] suggests that other factors such as age [4], sex [4, 5], genetics [6, 7] and environmental 
influences [6] affect the course of ALD [8]. 
The mechanisms underlying alcohol-induced liver damage are still largely unknown [9]. 
However, the pathogenesis involves multiple cell types and noxious factors such as oxidative stress 
and proinflammatory cytokines, especially tumor necrosis factor-alpha (TNF-α), which are directly  
involved in the pathogenesis of alcoholic hepatitis [6, 10, 11] and at the same time implicated in the 
down-regulation of hepatobiliary transport systems in both inflammatory and obstructive cholestasis 
[12]. Besides changes in transporter gene expression, ethanol also functionally impairs bile salt 
secretion by hepatocellular alterations in membrane fluidity and microtubule formation [13-15]. As 
expected from these experimental studies in rodents, a single small heterogenous human study in 
eleven human subjects with inflammatory cholestasis (7/11 with alcoholic hepatitis) demonstrated the 
down-regulation of major transport systems in liver biopsy tissue as an acquired component of 
cholestasis [16]. Other studies underlining the importance of hepatobiliary transport systems in 
alcoholic hepatitis have shown that the severity of cholestatic alcoholic hepatitis is associated with bile 
salt retention [17] which was suggested as an even more relevant prognostic indicator of outcome than 
jaundice [18]. Functionally, bile salt accumulation contributes to ethanol-induced hepatotoxicity, since 
hydrophobic bile salts aggravate steatosis, lipid peroxidation and cytolysis in rats fed an ethanol-
containing liquid diet [19]. Endogenous bile salts could therefore, in part, mediate ethanol-induced 
hepatotoxicity. It has even been proposed that elevation of total serum bile salt concentrations may 
actually correlate better with histologic progression of ALD than do standard biochemistries [13]. 
A possible interplay of bile acid homeostasis and vitamin D has been suggested recently. At 
least in mice, vitamin D has been involved in the activation of the intestinal hormone fibroblast growth 
factor 19 (FGF19) and subsequent receptor-mediated down-regulation of hepatic cytochrome P450 
7A1 (CYP7A1), the rate limiting enzyme in bile acid synthesis [20]. Decreased 25 OH-vitamin D 
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levels are a common phenomenon in patients with alcoholism and have been described in several 
studies even in the absence of advanced liver disease [21]. Furthermore, chronic ethanol consumption 
leads to the induction of the renal 1,25 (OH)2-vitamin D3-24-hydroxylase (CYP24A1) which is 
responsible for the inactivation of the active form of vitamin D3 [22]. Considering the well described 
anti-inflammatory, antiproliferative and immunomodulatory activities of vitamin D [23], 
hypovitaminosis D may play a relevant role in the progression of ALD. Therefore, the recently 
described cross-talk between vitamin D and bile acid synthesis renders the vitamin D receptor (VDR) 
another attractive target for genetic analysis in ALD.  
Genetic case control studies analyzing single nucleotide polymorphisms (SNP) of genes 
related to oxidative stress detected either no association with ALD, or produced conflicting results [6, 
7]. Genetic variants in genes implicated in Vitamin D homeostasis and bile trafficking have not been 
studied as yet, although the evidence detailed above render this hypothesis attractive. Thus, we set out 
to characterize the role of frequent genetic polymorphisms in the bile salt export pump (BSEP; 
ABCB11), the major driving force for bile flow, and the VDR (NR1I1) haplotype on the emergence of 
cirrhosis in patients with chronic ALD.  
 
Materials and methods 
 
Patients and study protocol 
131 Caucasian patients of central European descent with alcoholic liver cirrhosis from a 
previously reported cohort [24-26] were recruited and analyzed (cirrhosis group). For those previous 
studies [24-26], consecutive alcoholic patients of whom sufficient clinical data were available and who 
reflected past and/or present heavy alcohol consumption as defined by at least 60g/day for women and 
80g/day for men for more than 10 years were recruited between 2000 and 2009 in the participating 
centers. For confirming eligibility of patients, present alcohol consumption was quantified through 
interrogation during a face-to-face interview. All patients received a diagnosis of alcohol dependence 
(per DSM-IV criteria) by the consensus of 2 clinical psychiatrists. All patients underwent careful 
clinical examination, standard laboratory testing and abdominal ultrasound. Alcoholic liver cirrhosis 
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was detected through a liver biopsy or evidenced by unequivocal clinical and/or laboratory results 
including (i) standard blood tests (coagulation tests, serum albumin concentration, platelet count), (ii) 
cirrhosis-related complications including encephalopathy or ascites, (iii) abdominal ultrasound and/or 
computed tomography and (iv) detection of esophageal varices via upper gastrointestinal endoscopy as 
described [24]. Other causes of chronic liver disease were excluded in all patients. Testing for hepatitis 
B surface antigen, anti-hepatitis B core antibody, and third generation hepatitis C antibody enzyme-
linked immunosorbent assay was negative. To rule out hereditary hemochromatosis, serum levels of 
ferritin and transferrin saturation were determined, and neither clinical nor serological signs of 
autoimmune liver disease were detectable [24]. 
Alcoholics with normal appearance of the liver on ultrasound and normal liver enzyme levels 
were recruited as controls for the mentioned previous studies. Out of that cohort, 380 patients with 
sufficient available DNA were used as a control for our study. 
The study was approved by all the relevant local ethics committees, and all the patients 
provided written informed consent prior to inclusion. 
 
DNA isolation, storage and genotyping of ABCB11 and NR1I1 polymorphisms 
DNA was isolated from whole blood/PBMC using the QIAamp DNA Minikit (Qiagen, 
Hilden, Germany) and stored at -80°C. Genotyping of the SNP ABCB11 c.1331T>G (p.V444A, 
rs2287622) as well as of NR1I1 polymorphisms forming the bat-haplotype (rs1544410, rs7975232, 
rs731236) [27] was performed using standard TaqMan technology. Fluorogenic 5’-nuclease (TaqMan) 
assays on a ABIPRISM 7700 sequence detection system was used for SNP determination. 0.25μL 
probe solution and 2.5μL 2x Universal PCR Master-Mix (Applied Biosystems) were brought to 5μL 
with 10ng genomic DNA. All genotyping data were analyzed with the SDS 2.3 software. 
 
Haplotype analysis 
For haplotype reconstruction, the freely available Haploview software (Broad Institute of MIT 
and Harvard, Massachusetts, USA http://www.broadinstitute.org/mpg/haploview) was used. 
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Quantification of serum bile salt levels 
Serum bile salts were quantified using a commercially available enzymatic assay (Bile Acids 
Procedure 450, Trinity Biotech, Bray, Ireland) with a linear range of serum bile salt concentrations 
between 0 and 200 μmol/L [28]. Blood was routinely drawn in a fasting state in the morning between 
8 and 10 A.M. to avoid falsely high bile salt levels. 
 
Serum liver function tests 
Quantification of bilirubin and aspartate aminotransferase (AST) levels have been performed 
using standard autoanalyzer techniques. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 17.0 (The Predictive Analytics Company, 
Chicago, Illinois, USA). To evaluate the significance of the differences in allelic and genotypic 
frequencies between alcoholic patients with and without cirrhosis the χ2 test was used. The association 
of serum markers (bile salts, bilirubin and AST) to genotypes and respective haplotypes was 
investigated using the Spearman Rho correlation. Effects of age and gender on bile salt level and 
emergence of cirrhosis were analyzed using univariate and multiple logistic regression. Odds ratios 
with 95% confidence intervals (CI) were computed using logistic regression (Supplement 1). The 
needed number of patients within the two different groups of alcoholic patients was estimated under 
the assumption of similar allelic frequencies as in a previous Caucasian cohort study in hepatitis C 
infected patients where the minor allele frequency for BSEP (minor allele: c.1331C) was 73.2% in 
cirrhotics and 60.3% in controls [29]. The frequency of NR1I1 bAt[CCA]-haplotype in cirrhotic 
hepatitis C infected patients was 63.5% and 48.6% in controls [30]. Given these figures and our 
number of patients and controls we expected a power of 0.73 for BSEP (α=0.05) and 0.94 for CCA 
haplotype (α=0.05) when designing this study. 
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Results 
 
Patient characteristics 
A total of 511 patients addicted to alcohol, with and without cirrhosis, were included in this 
genetic cohort study for ABCB11 genotyping. Additionally, NR1I1 genotyping was performed for the 
321 patients of the same cohorts with sufficient remaining DNA. Cohort characteristics are shown in 
Table I. Frequencies of the determined genotypes and haplotypes in cirrhotic patients versus those 
without cirrhosis were analyzed. Furthermore, genotypes and haplotypes were correlated to liver 
function tests in the cirrhosis group, where individual data were available. By definition, all patients in 
the control group had normal liver function tests.  
Table I 
 
Genotype and allelic distribution of the ABCB11 c.1331T>G polymorphism according to fibrosis 
stage in alcoholic patients 
We determined the genotype and allelic frequency of the ABCB11 c.1331T>G SNP in the 
cohort of alcoholics with cirrhosis (n= 131) in comparison to the complete control cohort of patients 
without cirrhosis (n= 380) (Table II). The ABCB11 genotype distribution was similar to other studies 
in Caucasian European patients with intrahepatic cholestasis of pregnancy [31] and chronic hepatitis C 
infection [29]. No difference between the two cohorts could be detected for either genotype (data not 
shown) or allelic frequency (Figure 1).  
Table II 
 
Influence of the ABCB11 c.1331T>G polymorphism on liver function tests and serum bile salt 
levels in alcoholic cirrhosis patients  
The ABCB11 c.1331T>G polymorphism was also correlated with bilirubin and AST levels – 
markers for cholestasis and liver cell damage – as well as with bile salt levels in the subgroup of 
alcoholic cirrhosis patients (bilirubin n= 105, AST n= 105, bile salts n= 32). Carriers of the C allele 
showed a slight tendency towards higher bile salt levels compared to carriers of the T allele, although 
without statistical significance (median bile salt level for the C allele 58μmol/L vs. 42μmol/L for the T 
allele; p= 0.413) (Figure 2). A similar trend was observed for the CC genotype compared to ABCB11 
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c.1331TC or TT (data not shown). For both ABCB11 c.1331 alleles and respective genotypes, no 
relevant difference could be observed for either serum bilirubin or AST levels (data not shown). In 
line with this finding, no significant correlation of ABCB11 genotype to histological inflammatory 
activity was detectable in this study. 
 
Genotype and haplotype distribution of common NR1I1 SNPs according to fibrosis stage in 
alcoholic patients 
In analogy to the ABCB11 study, NR1I1 genotyping was performed for alcoholics with 
cirrhosis (n= 131) in order to investigate the genotype and allelic frequency in our cohort and 
compared to a control group of alcoholics without cirrhosis (n= 190 with sufficient DNA) (Table III). 
Again, the NR1I1 genotype distribution was comparable to previously published data in Caucasian 
European patients with chronic hepatitis C infection [30]. No significant difference in the distribution 
of genotypes (Table III) and haplotypes (Table IV) between cirrhosis patients and controls was found 
(Figure 3).  
Tables 
III & IV 
 
Influence of NR1I1 genotype and haplotype on liver function tests and serum bile salt levels in 
alcoholic cirrhosis patients  
Subsequently, NR1I1 genotypes and haplotypes were correlated with bilirubin, AST and bile 
salt levels in the subgroup of alcoholic cirrhosis patients (bilirubin n= 105, AST n= 105, bile salts n= 
32). For the bAt[CCA]-haplotype, a slight trend towards higher bile salt levels compared to all other 
NR1I1 haplotypes could be observed (median bile salt level for the bAt[CCA]-haplotype 58μmol/L vs. 
38μmol/L for all other NR1I1 haplotypes; p= 0.216) (Figure 4A). However, no such trend could be 
detected for the individual NR1I1 SNPs (Figure 4B, C, D). Similarly, no correlation between NR1I1 
genotypes / haplotype and serum bilirubin or AST levels were observed (data not shown). In support, 
no significant correlation of the bAt[CCA]-haplotype to histological inflammatory activity was 
detectable. 
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Discussion 
The present study investigated the genetic influence of the ABCB11 c.1331T>G polymorphism 
and the common NR1I1 bAt[CCA]-haplotype on the presence of liver cirrhosis in alcoholic patients. 
There are minor differences in the baseline characteristics between the two cohorts. As expected from 
the literature, median age in the cirrhosis group is about ten years higher than in the control cohort 
since development of cirrhosis typically develops with this interval during chronic liver damage. 
Given the absence of any clinicochemical or imaging pathologies in the non-cirrhotic controls the 
likelihood of chronic liver damage and subsequent development of cirrhosis is very low. Nevertheless, 
the unknown long term outcome of non-cirrhotic controls is a given limitation of this study. 
Differences in alcohol intake are not relevant for our findings since mean intake in the non-cirrhosis 
group even exceeds the cirrhosis group. 
Despite a slight trend towards bile salt retention in alcoholic cirrhosis patients carrying the 
ABCB11 c.1331T>G polymorphism and the common NR1I1 bAt[CCA]-haplotype, no increased 
frequency could be observed in the present study compared to our control cohort without liver 
damage. Similarly, earlier genetic studies analyzing single nucleotide polymorphisms in oxidative 
stress related genes did not show a clear association with ALD [6, 7]. The only robust genetic rsik 
factor for progressive ALD so far is a SNP in the gene coding for Patatin-like phospholipase domain-
containing protein 3 (PNPLA3; rs738409) which has been established quite recently [7, 26, 32]. 
The major driving force for bile flow represents the BSEP located in the canalicular membrane 
of hepatocytes [33]. Several studies have analyzed the role of SNPs and mutations in hepatobiliary 
transport systems. Low BSEP protein expression levels have been associated with the nonsynonymous 
c.1331C allele (p.444A) of ABCB11 [34] and elevated serum bile salt levels have been found in 
carriers of the “cholestatic” c.1331CC genotype in independent studies [29, 31]. The particular 
pathogenetic role of bile salt retention in ALD clearly correlates with histologic inflammatory scores 
and histologic progression [13, 17].  
Although largely negative, this study contains pathogenetic information for disease 
progression in ALD, at least in the differentiation from other forms of chronic liver disease. As such, 
polymorphisms in ABCB11 encoding for BSEP have been identified as risk factors for intrahepatic 
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cholestasis of pregnancy [31]. Further evidence exists for a role of BSEP in hereditary forms of 
cholestasis [33] as well as drug-induced cholestasis [35]. However, this polymorphism does not 
exclusively affect cholestatic liver disease, since the c.1331C allele (p.444A) of ABCB11 has recently 
also been associated with the progression to cirrhosis in chronic viral hepatitis C (HCV) patients [29]. 
The same trend towards increased serum bile salt levels observed for patients with intrahepatic 
cholestasis of pregnancy [31] and chronic viral hepatitis C [29] carrying the c.1331C allele (p.444A) 
of ABCB11 in independent studies can be detected in the present cohort. The fact that no correlation of 
ABCB11 c.1331C with advanced fibrosis has been observed in another large cohort of patients with 
non-alcoholic fatty liver disease [29] allows the conclusion that bile salt retention may not play a 
central role in the disease progression to cirrhosis in neither alcoholic nor non-alcoholic fatty liver 
disease which are histologically indiscernible. Nevertheless, at least in ALD the pivotal role of bile 
salt retention in the pathogenesis of acute liver injury and its prognosis remains unchallenged. 
Hypovitaminosis D is a common feature of alcoholism [21]. The well described anti-
inflammatory, antiproliferative and immunomodulatory activities of vitamin D and a recently 
described cross-talk between vitamin D and bile acid synthesis [20] render the vitamin D receptor 
(NR1I1) a second attractive target gene in ALD. In fact, genetic variations in the VDR (NR1I1) gene 
have been characterized as important modulators of multiple diseases including hepatic disorders such 
as primary biliary cirrhosis and autoimmune hepatitis [36, 37]. Recently, our group has identified a 
significant association between the NR1I1 bAt[CCA]-haplotype and fibrosis progression rate as well 
as development of cirrhosis in HCV patients [30]. VDR (NR1I1) haplotypes are also significantly 
associated with the occurrence of hepatocellular carcinoma in patients with liver cirrhosis [38]. Of 
note, this relationship is even more specific for patients with an alcoholic etiology. From these data, it 
appeared attractive to hypothesize a pathogenetic role of VDR (NR1I1) haplotypes in ALD. However, 
the present study does not support this assumption, since no increased frequency could be observed in 
alcoholic cirrhosis patients compared to a control cohort without liver damage.  
Certainly it would have been attractive to study the influence of NR1I1 SNPs on Vitamin D 
levels but unfortunately blood samples were no longer available. However, another recent study of our 
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group in HCV infected patients showed no correlation between VDR (NR1I1) polymorphism and 25-
OH vitamin D levels [30].  
Based on the assumption of a significant difference in previous genetic studies investigating 
ABCB11 and VDR genotypes / haplotypes in HCV patients the present study was a priori adequately 
powered. Given the minimal difference in minor allele frequencies for both genes even a tenfold 
number of patients would be marginal to detect significant differences with then questionable 
relevance. In conclusion, vitamin D receptor polymorphisms and the corresponding haplotype may not 
play a central role in cirrhosis development in patients with chronic alcohol consumption but this gene 
locus could contribute to the development of hepatocellular carcinoma as the most serious 
complication of endstage ALD. 
Taking into account the complexity of the pathogenesis of ALD and the fact that many genetic 
association studies have failed to show an association to disease progression [6, 7] one could 
hypothesise that one SNP alone may not be enough to significantly influence the course of the disease.  
Although the present study could not detect a significant genetic influence of the ABCB11 
p.V444A polymorphism and the common NR1I1 bAt[CCA]-haplotype on the presence of liver 
cirrhosis in patients with chronic alcohol abuse, our findings do not preclude a relevant role of bile 
salts and vitamin D in acute ALD. Whereas treatment with hydrophilic bile acids such as 
ursodeoxycholic acid has beneficial effects to limit bile acid toxicity but does not represent a 
therapeutic standard, substitution of vitamin D may be discussed in patients with any stage of ALD to 
correct for hypovitaminosis. 
 11
Funding 
This study was funded by the Hartmann Müller Foundation, Zurich, Switzerland (to P.F. and 
A.G.). 
 12
Acknowledgements 
The authors thank Jyrki Eloranta, Katharina Baur and Claudia Gottier for advice and excellent 
technical support, respectively. 
 13
References 
 
1. WHO, Global status report on alcohol and health, 2011, World Health Organization: Italy. p. 
85. 
2. Perz, J.F., et al., The contributions of hepatitis B virus and hepatitis C virus infections to 
cirrhosis and primary liver cancer worldwide. J Hepatol, 2006. 45(4): p. 529-38. 
3. Altamirano, J. and R. Bataller, Alcoholic liver disease: pathogenesis and new targets for 
therapy. Nat Rev Gastroenterol Hepatol, 2011. 8(9): p. 491-501. 
4. Raynard, B., et al., Risk factors of fibrosis in alcohol-induced liver disease. Hepatology, 2002. 
35(3): p. 635-8. 
5. Becker, U., et al., Prediction of risk of liver disease by alcohol intake, sex, and age: a 
prospective population study. Hepatology, 1996. 23(5): p. 1025-9. 
6. Wilfred de Alwis, N.M. and C.P. Day, Genetics of alcoholic liver disease and nonalcoholic 
fatty liver disease. Semin Liver Dis, 2007. 27(1): p. 44-54. 
7. Stickel, F. and J. Hampe, Genetic determinants of alcoholic liver disease. Gut, 2012. 61(1): p. 
150-9. 
8. Lucey, M.R., P. Mathurin, and T.R. Morgan, Alcoholic hepatitis. N Engl J Med, 2009. 
360(26): p. 2758-69. 
9. Miller, A.M., et al., Molecular Mechanisms of Alcoholic Liver Disease: Innate Immunity and 
Cytokines. Alcohol Clin Exp Res, 2011. 
10. Yin, M., et al., Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in 
mice. Gastroenterology, 1999. 117(4): p. 942-52. 
11. McClain, C.J., et al., Recent advances in alcoholic liver disease. IV. Dysregulated cytokine 
metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol, 2004. 287(3): 
p. G497-502. 
12. Geier, A., et al., Effects of proinflammatory cytokines on rat organic anion transporters 
during toxic liver injury and cholestasis. Hepatology, 2003. 38(2): p. 345-54. 
13. Tung, B.Y. and R.L. Carithers, Cholestasis and alcoholic liver disease. Clin Liver Dis, 1999. 
3(3): p. 585-601. 
14. Mills, P.R., et al., The effect of changes in the fluid state of rat liver plasma membrane on the 
transport of taurocholate. Hepatology, 1987. 7(1): p. 61-6. 
15. Gregory, D.H., et al., Mechanism of secretion of biliary lipids: role of a microtubular system 
in hepatocellular transport of biliary lipids in the rat. Gastroenterology, 1978. 74(1): p. 93-
100. 
16. Zollner, G., et al., Hepatobiliary transporter expression in percutaneous liver biopsies of 
patients with cholestatic liver diseases. Hepatology, 2001. 33(3): p. 633-46. 
17. Trinchet, J.C., et al., Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with 
usual liver tests and histological features. J Hepatol, 1994. 21(2): p. 235-40. 
18. Nissenbaum, M., et al., Prognostic significance of cholestatic alcoholic hepatitis. VA 
Cooperative Study Group #119. Dig Dis Sci, 1990. 35(7): p. 891-6. 
19. Montet, A.M., et al., Bile salts modulate chronic ethanol-induced hepatotoxicity. Alcohol 
Alcohol, 2002. 37(1): p. 25-9. 
20. Schmidt, D.R., et al., Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol 
Chem, 2010. 285(19): p. 14486-94. 
21. Malik, P., et al., Low bone mineral density and impaired bone metabolism in young alcoholic 
patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res, 2009. 33(2): p. 
375-81. 
22. Shankar, K., et al., Chronic ethanol consumption leads to disruption of vitamin D3 
homeostasis associated with induction of renal 1,25 dihydroxyvitamin D3-24-hydroxylase 
(CYP24A1). Endocrinology, 2008. 149(4): p. 1748-56. 
23. Nagpal, S., S. Na, and R. Rathnachalam, Noncalcemic actions of vitamin D receptor ligands. 
Endocr Rev, 2005. 26(5): p. 662-87. 
24. Stickel, F., et al., No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 
as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res, 2008. 32(6): p. 
959-65. 
 14
25. Treutlein, J., et al., Genome-wide association study of alcohol dependence. Arch Gen 
Psychiatry, 2009. 66(7): p. 773-84. 
26. Stickel, F., et al., Genetic variation in the PNPLA3 gene is associated with alcoholic liver 
injury in caucasians. Hepatology, 2010. 
27. Uitterlinden, A.G., et al., Genetics and biology of vitamin D receptor polymorphisms. Gene, 
2004. 338(2): p. 143-56. 
28. Roda, A., et al., Bioluminescence measurement of primary bile acids using immobilized 7 
alpha-hydroxysteroid dehydrogenase: application to serum bile acids. J Lipid Res, 1982. 
23(9): p. 1354-61. 
29. Iwata, R., et al., A common polymorphism in the ABCB11 gene is associated with advanced 
fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond), 2011. 
120(7): p. 287-96. 
30. Baur, K., et al., Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin D 
Receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int, in press, 
2011. 
31. Meier, Y., et al., Increased susceptibility for intrahepatic cholestasis of pregnancy and 
contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt 
export pump. World J Gastroenterol, 2008. 14(1): p. 38-45. 
32. Tian, C., et al., Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet, 
2010. 42(1): p. 21-3. 
33. Stieger, B., Y. Meier, and P.J. Meier, The bile salt export pump. Pflugers Arch, 2007. 453(5): 
p. 611-20. 
34. Meier, Y., et al., Interindividual variability of canalicular ATP-binding-cassette (ABC)-
transporter expression in human liver. Hepatology, 2006. 44(1): p. 62-74. 
35. Lang, C., et al., Mutations and polymorphisms in the bile salt export pump and the multidrug 
resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics, 
2007. 17(1): p. 47-60. 
36. Valdivielso, J.M. and E. Fernandez, Vitamin D receptor polymorphisms and diseases. Clin 
Chim Acta, 2006. 371(1-2): p. 1-12. 
37. Vogel, A., C.P. Strassburg, and M.P. Manns, Genetic association of vitamin D receptor 
polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology, 2002. 
35(1): p. 126-31. 
38. Falleti, E., et al., Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in 
alcoholic cirrhosis. World J Gastroenterol, 2010. 16(24): p. 3016-24. 
 
 
 15
 16
Legends to figures 
 
Fig. 1: Comparison of allelic frequencies of ABCB11 c.1331T>G between alcoholic patients with 
and without cirrhosis. 
χ2 test revealed no significant differences in the distribution of alleles between the groups of patients 
with and without cirrhosis (p= 0.559). 
 
Fig. 2: Correlation of ABCB11 c.1331T>G with serum bile salt levels. 
In alcoholic patients with cirrhosis bile salt levels were correlated to ABCB11 c.1331 T and C alleles 
using Spearman Rho correlation. The C allele showed a trend towards higher bile salt levels compared 
to the T allele (median bile salt level for the C allele 58μmol/L vs. 42μmol/L for the T allele; p= 0.413).  
 
Fig. 3: Comparison of NR1I1 allelic haplotype and individual allele frequencies between 
alcoholics with and without cirrhosis. 
(A) χ2 test revealed no significant differences in the distribution of the three most frequent haplotypes 
between the two cohorts (p= 0.630). (B-D) Neither of the individual NR1I1 allele frequencies 
significantly differed between cirrhosis patients and controls (p= 0.618 for BsmI, p= 0.689 for ApaI 
and p= 0.935 for TaqI).  
 
Fig. 4: Correlation of NR1I1 allelic haplotype and individual alleles with serum bile salt levels. 
(A) In alcoholic patients with cirrhosis, bile salt levels were correlated to NR1I1 haplotypes using 
Spearman Rho correlation. The bAt[CCA]-haplotype showed a slight trend towards higher bile salt 
levels compared to other NR1I1 haplotypes (median bile salt level for the bAt[CCA]-haplotype 
58μmol/L vs. 38μmol/L for all other NR1I1 haplotypes; p= 0.216). (B-D) No correlation between the 
alleles of individual NR1I1 SNPs and serum bile salt levels could be detected (p= 0.223 for BsmI, p= 
0.303 for ApaI and p= 0.265 for TaqI).  
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Supplement 1: Univariate and multivariate analysis 
 
 
Univariate Analysis association to cirrhosis 
Parameter OR (95% CI) P 
Age (>45 vs. <45 yrs) 7.50 (5.02 – 11.21) 0.000 
Gender (male vs. female) 1.44 (0.99 – 2.09) 0.058 
BSEP (C vs. T) 1.10 (0.82 – 1.47) 0.526 
Bsm I (C vs. T) 1.10 (0.79 – 1.52) 0.586 
Apa I (A vs. C) 1.07 (0.78 – 1.46) 0.683 
Taq I (A vs. G) 1.03 (0.74 – 1.42) 0.875 
Haplotype (CCA vs. TAG & CAA) 0.98 (0.71 – 1.36) 0.920 
Multivariate Analysis BSEP and cirrhosis 
Parameter OR (95% CI) P 
Age (>45 vs. <45 yrs) 7.01 (4.68 – 10.50) 0.000 
Gender (male vs. female) 1.45 (0.96 – 2.20) 0.080 
BSEP (C vs. T) 1.16 (0.84 – 1.61) 0.370 
 
Multivariate Analysis Bsm I and cirrhosis 
Parameter OR (95% CI) P 
Age (>45 vs. <45 yrs) 14.20 (8.73 – 23.10) 0.000 
Gender (male vs. female) 0.49 (0.27 – 0.88) 0.016 
Bsm I (C vs. T) 0.85 (0.56 – 1.28) 0.435 
 
Multivariate Analysis Apa I and cirrhosis 
Parameter OR (95% CI) P 
Age (>45 vs. <45 yrs) 12.96 (8.15 – 20.62) 0.000 
Gender (male vs. female) 0.57 (0.32 – 1.00) 0.052 
Apa I (A vs. C) 1.49 (1.00 – 2.22) 0.052 
 
Multivariate Analysis Taq I and cirrhosis 
Parameter OR (95% CI) P 
Age (>45 vs. <45 yrs) 14.06 (8.76 – 22.56) 0.000 
Gender (male vs. female) 0.54 (0.30 – 0.96) 0.036 
Taq I (A vs. G) 0.82 (0.54 – 1.23) 0.331 
 
Multivariate Analysis VDR-Haplotype and cirrhosis 
Parameter OR (95% CI) P 
Age (>45 vs. <45 yrs) 14.52 (8.87 – 23.75) 0.000 
Gender (male vs. female) 0.50 (0.28 – 0.90) 0.021 
Haplotype (CCA vs. TAG & CAA) 0.71 (0.47 – 1.07) 0.105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Univariate Analysis association to bile salt levels (>50μmol/L vs. <50μmol/L) 
Parameter OR (95% CI) P 
Age (<45 vs. >45 yrs) 1.14 (0.15 – 8.65) 0.897 
Gender (female vs. male) 1.27 (0.36 – 4.50) 0.708 
BSEP (C vs. T) 1.58 (0.57 – 4.37) 0.379 
Bsm I (C vs. T) 1.41 (0.49 – 4.04) 0.520 
Apa I (C vs. A) 1.85 (0.68 – 5.00) 0.228 
Taq I (A vs. G) 1.36 (0.50 – 3.73) 0.545 
Haplotype (CCA vs. TAG & CAA) 1.83 (0.62 – 5.43) 0.275 
 
Multivariate Analysis BSEP and bile salt levels (>50μmol/L vs. <50μmol/L) 
Parameter OR (95% CI) P 
Age (<45 vs. >45 yrs) 1.07 (0.10 – 12.06) 0.958 
Gender (female vs. male) 1.27 (0.28 – 5.75) 0.752 
BSEP (C vs. T) 1.68 (0.59 – 4.79) 0.330 
 
Multivariate Analysis Bsm I and bile salt levels (>50μmol/L vs. <50μmol/L) 
Parameter OR (95% CI) P 
Age (<45 vs. >45 yrs) 1.00 (0.90 – 11.09) 1.000 
Gender (female vs. male) 1.21 (0.26 – 5.57) 0.805 
Bsm I (C vs. T) 1.37 (0.47 – 4.00) 0.563 
 
Multivariate Analysis Apa I and bile salt levels (>50μmol/L vs. <50μmol/L) 
Parameter OR (95% CI) P 
Age (<45 vs. >45 yrs) 1.18 (0.10 – 13.49) 0.897 
Gender (female vs. male) 1.25 (0.28 – 5.67) 0.774 
Apa I (C vs. A) 1.90 (0.68 – 5.28) 0.221 
 
Multivariate Analysis Taq I and bile salt levels (>50μmol/L vs. <50μmol/L) 
Parameter OR (95% CI) P 
Age (<45 vs. >45 yrs) 1.00 (0.90 – 11.10) 1.000 
Gender (female vs. male) 1.20 (0.26 – 5.42) 0.815 
Taq I (A vs. G) 1.39 (0.49 – 3.93) 0.534 
 
Multivariate Analysis VDR-Haplotype and bile salt levels (>50μmol/L vs. <50μmol/L) 
Parameter OR (95% CI) P 
Age (<45 vs. >45 yrs) 1.18 (0.10 – 13.55) 0.896 
Gender (female vs. male) 1.36 (0.29 – 6.33) 0.692 
Haplotype (CCA vs. TAG & CAA) 1.90 (0.63 – 5.74) 0.253 
 
